欧洲-话题@MedSci

#欧洲#

592篇内容 | 6060人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1339363, encodeId=9ab11339363d3, content=<a href='/topic/show?id=447663054f5' target=_blank style='color:#2F92EE;'>#欧洲#</a>, objectTitle=PARP抑制剂Lynparza在欧洲获得重大成功！同时获批治疗卵巢癌和前列腺癌, objectType=article, longId=203200, objectId=12e720320011, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=12e720320011, replyNumber=0, likeNumber=102, createdTime=2020-11-11, rootId=0, userName=ms9474365431325850, userId=5c442500150, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=12e720320011, moduleTitle=PARP抑制剂Lynparza在欧洲获得重大成功！同时获批治疗卵巢癌和前列腺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=12e720320011)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1339362, encodeId=79df13393620c, content=<a href='/topic/show?id=447663054f5' target=_blank style='color:#2F92EE;'>#欧洲#</a>, objectTitle=多国实行封闭，欧洲第二波疫情气势汹汹！, objectType=article, longId=202616, objectId=23b0202616f0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=23b0202616f0, replyNumber=0, likeNumber=22, createdTime=2020-10-31, rootId=0, userName=ms9474365431325850, userId=5c442500150, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=23b0202616f0, moduleTitle=多国实行封闭，欧洲第二波疫情气势汹汹！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=23b0202616f0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1339361, encodeId=e17713393610a, content=<a href='/topic/show?id=447663054f5' target=_blank style='color:#2F92EE;'>#欧洲#</a>, objectTitle=欧洲人用药品委员会（CHMP）10月会议，积极推荐十款新药上市, objectType=article, longId=202357, objectId=385420235e4d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=385420235e4d, replyNumber=0, likeNumber=82, createdTime=2020-10-23, rootId=0, userName=ms9474365431325850, userId=5c442500150, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=385420235e4d, moduleTitle=欧洲人用药品委员会（CHMP）10月会议，积极推荐十款新药上市, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=385420235e4d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1339360, encodeId=6ba1133936006, content=<a href='/topic/show?id=447663054f5' target=_blank style='color:#2F92EE;'>#欧洲#</a>, objectTitle=10月19日全球新冠肺炎（COVID-19）疫情简报，确诊超4024万，欧洲全面爆发第二波疫情, objectType=article, longId=202278, objectId=b6e52022e8e3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b6e52022e8e3, replyNumber=0, likeNumber=73, createdTime=2020-10-20, rootId=0, userName=ms9474365431325850, userId=5c442500150, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b6e52022e8e3, moduleTitle=10月19日全球新冠肺炎（COVID-19）疫情简报，确诊超4024万，欧洲全面爆发第二波疫情, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b6e52022e8e3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1339359, encodeId=63fb13393591c, content=<a href='/topic/show?id=447663054f5' target=_blank style='color:#2F92EE;'>#欧洲#</a>, objectTitle=Lancet Global Health：新西兰毛利人、太平洋裔及欧洲裔II型糖尿病患者预后差异研究, objectType=article, longId=202234, objectId=5cdd202234f3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5cdd202234f3, replyNumber=0, likeNumber=74, createdTime=2020-10-19, rootId=0, userName=ms9474365431325850, userId=5c442500150, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5cdd202234f3, moduleTitle=Lancet Global Health：新西兰毛利人、太平洋裔及欧洲裔II型糖尿病患者预后差异研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5cdd202234f3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1339358, encodeId=b7b81339358d7, content=<a href='/topic/show?id=447663054f5' target=_blank style='color:#2F92EE;'>#欧洲#</a>, objectTitle=Efruxifermin（EFX）治疗NASH：已获欧洲药品管理局的“优先药物称号”（PRIME）, objectType=article, longId=202223, objectId=a05920222388, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a05920222388, replyNumber=0, likeNumber=67, createdTime=2020-10-18, rootId=0, userName=ms9474365431325850, userId=5c442500150, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a05920222388, moduleTitle=Efruxifermin（EFX）治疗NASH：已获欧洲药品管理局的“优先药物称号”（PRIME）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a05920222388)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1339357, encodeId=b3eb133935e64, content=<a href='/topic/show?id=447663054f5' target=_blank style='color:#2F92EE;'>#欧洲#</a>, objectTitle=降脂神药！一年给药2次，药效持续17个月，诺华的siPCSK9疗法inclisiran获得欧洲CHMP的正面评价, objectType=article, longId=202221, objectId=a2c720222179, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a2c720222179, replyNumber=0, likeNumber=89, createdTime=2020-10-18, rootId=0, userName=ms9474365431325850, userId=5c442500150, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a2c720222179, moduleTitle=降脂神药！一年给药2次，药效持续17个月，诺华的siPCSK9疗法inclisiran获得欧洲CHMP的正面评价, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a2c720222179)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1339356, encodeId=115713393562e, content=<a href='/topic/show?id=447663054f5' target=_blank style='color:#2F92EE;'>#欧洲#</a>, objectTitle=研究称美国洛杉矶早期新冠病毒可能主要源自欧洲, objectType=article, longId=202012, objectId=75bd20201239, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=75bd20201239, replyNumber=0, likeNumber=62, createdTime=2020-10-13, rootId=0, userName=ms9474365431325850, userId=5c442500150, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=75bd20201239, moduleTitle=研究称美国洛杉矶早期新冠病毒可能主要源自欧洲, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=75bd20201239)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1339355, encodeId=eb9b133935577, content=<a href='/topic/show?id=447663054f5' target=_blank style='color:#2F92EE;'>#欧洲#</a>, objectTitle=恒瑞医药正在瑞士巴塞尔建立欧洲临床研发中心, objectType=article, longId=201859, objectId=60cd2018593c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=60cd2018593c, replyNumber=0, likeNumber=69, createdTime=2020-10-10, rootId=0, userName=ms9474365431325850, userId=5c442500150, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=60cd2018593c, moduleTitle=恒瑞医药正在瑞士巴塞尔建立欧洲临床研发中心, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=60cd2018593c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1339354, encodeId=de4013393541f, content=<a href='/topic/show?id=447663054f5' target=_blank style='color:#2F92EE;'>#欧洲#</a>, objectTitle=Nature：中国人很安全，新冠重症风险遗传自灭绝的尼安德特人，印度和欧洲人风险高, objectType=article, longId=201654, objectId=ac0b201654ef, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ac0b201654ef, replyNumber=0, likeNumber=64, createdTime=2020-10-06, rootId=0, userName=ms9474365431325850, userId=5c442500150, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ac0b201654ef, moduleTitle=Nature：中国人很安全，新冠重症风险遗传自灭绝的尼安德特人，印度和欧洲人风险高, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ac0b201654ef)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1339353, encodeId=21e61339353fe, content=<a href='/topic/show?id=447663054f5' target=_blank style='color:#2F92EE;'>#欧洲#</a>, objectTitle=欧洲委员会（EC）批准CRYSVITA（burosumab）治疗老年人和成年人X连锁性低磷血症（XLH）, objectType=article, longId=201574, objectId=8f992015e4ca, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8f992015e4ca, replyNumber=0, likeNumber=68, createdTime=2020-10-05, rootId=0, userName=ms9474365431325850, userId=5c442500150, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8f992015e4ca, moduleTitle=欧洲委员会（EC）批准CRYSVITA（burosumab）治疗老年人和成年人X连锁性低磷血症（XLH）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8f992015e4ca)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1339352, encodeId=764c13393520d, content=<a href='/topic/show?id=447663054f5' target=_blank style='color:#2F92EE;'>#欧洲#</a>, objectTitle=GUT：2013年后欧洲各国幽门螺杆菌临床管理效果评估, objectType=article, longId=201359, objectId=7e0520135990, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7e0520135990, replyNumber=0, likeNumber=97, createdTime=2020-09-30, rootId=0, userName=ms9474365431325850, userId=5c442500150, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7e0520135990, moduleTitle=GUT：2013年后欧洲各国幽门螺杆菌临床管理效果评估, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7e0520135990)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1339351, encodeId=7cb31339351dc, content=<a href='/topic/show?id=447663054f5' target=_blank style='color:#2F92EE;'>#欧洲#</a>, objectTitle=Sci Rep:如何应对新冠二次暴发？新研究通过预测模型成功模拟欧洲二次疫情发展形势, objectType=article, longId=201261, objectId=9bfb201261be, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9bfb201261be, replyNumber=0, likeNumber=69, createdTime=2020-09-28, rootId=0, userName=ms9474365431325850, userId=5c442500150, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9bfb201261be, moduleTitle=Sci Rep:如何应对新冠二次暴发？新研究通过预测模型成功模拟欧洲二次疫情发展形势, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9bfb201261be)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1339350, encodeId=04671339350f7, content=<a href='/topic/show?id=447663054f5' target=_blank style='color:#2F92EE;'>#欧洲#</a>, objectTitle=2019年欧洲骨质疏松和骨关节炎临床经济学会(ESCEO)对膝骨关节炎的管理建议, objectType=article, longId=199890, objectId=873019989013, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=873019989013, replyNumber=0, likeNumber=91, createdTime=2020-08-26, rootId=0, userName=ms9474365431325850, userId=5c442500150, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=873019989013, moduleTitle=2019年欧洲骨质疏松和骨关节炎临床经济学会(ESCEO)对膝骨关节炎的管理建议, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=873019989013)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1339349, encodeId=93e413393494a, content=<a href='/topic/show?id=447663054f5' target=_blank style='color:#2F92EE;'>#欧洲#</a>, objectTitle=全球改善结肠镜检查结果的口服药物Methylene Blue MMX，在欧洲获批, objectType=article, longId=199856, objectId=7f37199856fa, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7f37199856fa, replyNumber=0, likeNumber=72, createdTime=2020-08-24, rootId=0, userName=ms9474365431325850, userId=5c442500150, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7f37199856fa, moduleTitle=全球改善结肠镜检查结果的口服药物Methylene Blue MMX，在欧洲获批, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7f37199856fa)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1339348, encodeId=a5f613393481b, content=<a href='/topic/show?id=447663054f5' target=_blank style='color:#2F92EE;'>#欧洲#</a>, objectTitle=Eur Heart J: 优化房颤治疗有4个环节！欧洲心脏杂志多项研究评述, objectType=article, longId=199605, objectId=f096199605b7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f096199605b7, replyNumber=0, likeNumber=85, createdTime=2020-08-19, rootId=0, userName=ms9474365431325850, userId=5c442500150, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f096199605b7, moduleTitle=Eur Heart J: 优化房颤治疗有4个环节！欧洲心脏杂志多项研究评述, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f096199605b7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1339347, encodeId=01fa133934e09, content=<a href='/topic/show?id=447663054f5' target=_blank style='color:#2F92EE;'>#欧洲#</a>, objectTitle=夏天高压低于110要减药！欧洲血压季节性变化共识, objectType=article, longId=199299, objectId=dcfc19929904, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=dcfc19929904, replyNumber=0, likeNumber=45, createdTime=2020-08-14, rootId=0, userName=ms9474365431325850, userId=5c442500150, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=dcfc19929904, moduleTitle=夏天高压低于110要减药！欧洲血压季节性变化共识, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=dcfc19929904)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1339346, encodeId=30b81339346cf, content=<a href='/topic/show?id=447663054f5' target=_blank style='color:#2F92EE;'>#欧洲#</a>, objectTitle=J Hypertens：夏天高压低于110要减药！欧洲血压季节性变化共识, objectType=article, longId=199212, objectId=7a4d19921222, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7a4d19921222, replyNumber=0, likeNumber=69, createdTime=2020-08-13, rootId=0, userName=ms9474365431325850, userId=5c442500150, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7a4d19921222, moduleTitle=J Hypertens：夏天高压低于110要减药！欧洲血压季节性变化共识, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7a4d19921222)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1339345, encodeId=095113393452a, content=<a href='/topic/show?id=447663054f5' target=_blank style='color:#2F92EE;'>#欧洲#</a>, objectTitle=奥马珠单抗在欧洲获批，成为治疗严重慢性鼻-鼻窦炎的**IgE单抗, objectType=article, longId=198981, objectId=4363198981ee, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4363198981ee, replyNumber=0, likeNumber=74, createdTime=2020-08-09, rootId=0, userName=ms9474365431325850, userId=5c442500150, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4363198981ee, moduleTitle=奥马珠单抗在欧洲获批，成为治疗严重慢性鼻-鼻窦炎的**IgE单抗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4363198981ee)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1339344, encodeId=1dcf1339344db, content=<a href='/topic/show?id=447663054f5' target=_blank style='color:#2F92EE;'>#欧洲#</a>, objectTitle=也是**一个靶向PIK3CA突变乳腺癌的药物Piqray，在欧洲获批, objectType=article, longId=198589, objectId=2f9119858915, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2f9119858915, replyNumber=0, likeNumber=63, createdTime=2020-08-03, rootId=0, userName=ms9474365431325850, userId=5c442500150, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2f9119858915, moduleTitle=也是**一个靶向PIK3CA突变乳腺癌的药物Piqray，在欧洲获批, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2f9119858915)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

欧洲

2020-05-29

ms9474365431325850 (审核中...)

前往app查看评论内容

#欧洲#

PARP抑制剂Lynparza在欧洲获得重大成功！同时获批治疗卵巢癌和前列腺癌

2020-11-11

ms9474365431325850 (审核中...)

前往app查看评论内容

#欧洲#

多国实行封闭，欧洲第二波疫情气势汹汹！

2020-10-31

ms9474365431325850 (审核中...)

前往app查看评论内容

#欧洲#

欧洲人用药品委员会（CHMP）10月会议，积极推荐十款新药上市

2020-10-23

ms9474365431325850 (审核中...)

前往app查看评论内容

#欧洲#

10月19日全球新冠肺炎（COVID-19）疫情简报，确诊超4024万，欧洲全面爆发第二波疫情

2020-10-20

ms9474365431325850 (审核中...)

前往app查看评论内容

#欧洲#

Lancet Global Health：新西兰毛利人、太平洋裔及欧洲裔II型糖尿病患者预后差异研究

2020-10-19

ms9474365431325850 (审核中...)

前往app查看评论内容

#欧洲#

Efruxifermin（EFX）治疗NASH：已获欧洲药品管理局的“优先药物称号”（PRIME）

2020-10-18

ms9474365431325850 (审核中...)

前往app查看评论内容

#欧洲#

降脂神药！一年给药2次，药效持续17个月，诺华的siPCSK9疗法inclisiran获得欧洲CHMP的正面评价

2020-10-18

ms9474365431325850 (审核中...)

前往app查看评论内容

#欧洲#

研究称美国洛杉矶早期新冠病毒可能主要源自欧洲

2020-10-13

ms9474365431325850 (审核中...)

前往app查看评论内容

#欧洲#

恒瑞医药正在瑞士巴塞尔建立欧洲临床研发中心

2020-10-10

ms9474365431325850 (审核中...)

前往app查看评论内容

#欧洲#

Nature：中国人很安全，新冠重症风险遗传自灭绝的尼安德特人，印度和欧洲人风险高

2020-10-06

ms9474365431325850 (审核中...)

前往app查看评论内容

#欧洲#

欧洲委员会（EC）批准CRYSVITA（burosumab）治疗老年人和成年人X连锁性低磷血症（XLH）

2020-10-05

ms9474365431325850 (审核中...)

前往app查看评论内容

#欧洲#

GUT：2013年后欧洲各国幽门螺杆菌临床管理效果评估

2020-09-30

ms9474365431325850 (审核中...)

前往app查看评论内容

#欧洲#

Sci Rep:如何应对新冠二次暴发？新研究通过预测模型成功模拟欧洲二次疫情发展形势

2020-09-28

ms9474365431325850 (审核中...)

前往app查看评论内容

#欧洲#

2019年欧洲骨质疏松和骨关节炎临床经济学会(ESCEO)对膝骨关节炎的管理建议

2020-08-26

ms9474365431325850 (审核中...)

前往app查看评论内容

#欧洲#

全球改善结肠镜检查结果的口服药物Methylene Blue MMX，在欧洲获批

2020-08-24

ms9474365431325850 (审核中...)

前往app查看评论内容

#欧洲#

Eur Heart J: 优化房颤治疗有4个环节！欧洲心脏杂志多项研究评述

2020-08-19

ms9474365431325850 (审核中...)

前往app查看评论内容

#欧洲#

夏天高压低于110要减药！欧洲血压季节性变化共识

2020-08-14

ms9474365431325850 (审核中...)

前往app查看评论内容

#欧洲#

J Hypertens：夏天高压低于110要减药！欧洲血压季节性变化共识

2020-08-13

ms9474365431325850 (审核中...)

前往app查看评论内容

#欧洲#

奥马珠单抗在欧洲获批，成为治疗严重慢性鼻-鼻窦炎的**IgE单抗

2020-08-09

ms9474365431325850 (审核中...)

前往app查看评论内容

#欧洲#

也是**一个靶向PIK3CA突变乳腺癌的药物Piqray，在欧洲获批

2020-08-03

科室
- - 订阅+
  - 更多科室
工具
服务